Pure Global AI
NCT06335173Recruiting

A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease
Acumen PharmaceuticalsPhase 2/3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Alzheimer Disease
Drug/Device/Intervention
ACU193
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Acumen Pharmaceuticals
Location
Phoenix,Carlsbad,Fullerton,Irvine,Long Beach,San Diego,Santa Ana,Sherman Oaks,Boulder,Denver,New Haven,Norwalk,Washington,Atlantis,Bradenton,Coral Gables,Delray Beach,Homestead,Lady Lake,Miami,Miami,N, Canada,France,Germany,Italy,Poland,Spain,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 2/3
Start date
Feb 29, 2024
End date
Jan 01, 2031
Enrollment
2040 participants
Primary outcome

Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score

Summary

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions
 administered once every four weeks (Q4W) in slowing cognitive and functional decline as
 compared to placebo in participants with early Alzheimer's disease.

ICD-10 classifications
Alzheimer diseaseAlzheimer disease, unspecifiedOther Alzheimer diseaseDementia in Alzheimer diseaseDementia in Alzheimer disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06335173
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06335173 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Acumen Pharmaceuticals and is currently Recruiting. The study focuses on Alzheimer Disease. Target enrollment is 2040 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.